MedTrace Logo

Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging

NCT03105609 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2019-02-05

No results posted yet for this study

Summary

Clinical trial investigating the role of hyperspectral imaging in the management of patients undergoing standard clinical treatment for naive neovascular choroidal membranes in age-related macular degeneration.

Conditions

  • Macular Degeneration
  • Choroidal Neovascularization

Interventions

DEVICE

Hyperspectral imaging

Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.

Sponsors & Collaborators

Principal Investigators

  • Marc G Sarossy, FRANZCO · Principal Investigator

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2018-12-01
Completion
2018-12-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03105609 on ClinicalTrials.gov